Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi (SASY.PA), opens new tab.
Novavax (NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its ...
In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...
Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback